|Dr. Jerel A. Banks M.D., Ph.D.||Exec. Chairman & CEO||539.96k||N/A||1975|
|Ms. Megan Joan Boston BComm, CA, Dip., GAICD||Exec. Director||329.46k||N/A||1972|
|Mr. Bryan Dulhunty||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Michael Graham||Head of Discovery & Founding Scientist||N/A||N/A||N/A|
|Dr. Craig Lewis||Chief Medical Adviser||N/A||N/A||N/A|
|Dr. Claudia Kloth||Sr. VP of Manufacturing||N/A||N/A||N/A|
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.